Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Capricor reported a second quarter net loss of $40.7 million, or $0.70 per share, with zero revenue, reducing its cash position to $237.9 million from $318.1 million at year-end. The company highlighted a negative FDA Advisory Committee outcome, where the panel voted 9-3 against sufficient evidence for Deramiocel's efficacy in DMD cardiomyopathy, though the primary upper limb endpoint was successful and published in The Lancet.
Key figures
- Cash
- 237900000
- Net Loss
- 40700000
- Revenue
- 0
- Drug Name
- Deramiocel
- Phase Of Trial
- Phase 3
- Operating Expenses
- 42900000
- Ad comm votes for
- 3
- Cash prior year end
- 318100000
- Ad comm votes against
- 9
- Hope3 primary p value
- 0.029
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.